Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Bessede, Alban; Marabelle, Aurélien; Guégan, Jean-Philippe; Danlos, François‐Xavier; Cousin, Sophie; Peyraud, F.; Chaput, Nathalie; Spalato, Mariella; Roubaud, Guilhem; Cabart, Mathilde; Khettab, Mohamed; Chaibi, A.; Rey, Christophe; Nafia, Imane; Mahon, F. X.; Soria, Jean‐Charles; Italiano, Antoîne

doi:10.1016/j.annonc.2022.05.010

Cited by 29 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Considering that such patients mentioned above may experience a long term stabilization or a slow smooth progression with ICIT, a simultaneous cancer pain management approach will definitely be necessary. Here, the problem will be that some of the drugs including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, acetaminophen and opioids have an interaction with ICIT agents involving pharmacodynamics and pharmacokinetics [62][63][64]. Table 5 presents class and type of drugs used in cancer pain management.…”

Section: Cancer Pain Management Throughout Icitmentioning

confidence: 99%

Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Strategy Against Tumor Plasticity

Hendekli¹

2023

Preprint

View full text Add to dashboard Cite

Immune checkpoint inhibition therapy (ICIT) is an emerging field in oncology especially opening new horizons to chemotherapy refractory patients. This paper provides deep insight into immune related adverse events (irAEs) posing a major challenge and drawback to ICIT, and presents right management strategies for very complex complications. Moreover, a non-linear mathematical approach to measure the ICIT success rate and a strategy to overcome or to delay the progression after initial good response to ICIT in a subset of patients are presented, respectively.

show abstract

Section: Cancer Pain Management Throughout Icitmentioning

confidence: 99%

Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Strategy Against Tumor Plasticity

Hendekli¹

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…13 Traditional cancer pain management strategy Considering that such patients mentioned above may experience a long term stabilization or a slow smooth progression with ICIT, a simultaneous cancer pain management approach will definitely be necessary. Here, the problem will be that some of the drugs including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, acetaminophen and opioids have an interaction with ICIT agents involving pharmacodynamics and pharmacokinetics [62][63][64]. It shall also be noted that in addition to the drug scheme shown in the above table several adjuvant analgesic medications such as antidepressants, anticonvulsants and bisphosphonates are also used in cancer pain management posing again risk of interaction with ICIT drugs.…”

Section: Cancer Pain Management Throughout Icitmentioning

confidence: 99%

Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy Against Tumor Plasticity

Hendekli¹

2023

Preprint

View full text Add to dashboard Cite

Immune checkpoint inhibition therapy (ICIT) is an emerging field in oncology especially opening new horizons to chemotherapy refractory patients. This paper provides deep insight into immune related adverse events (irAEs) posing a major challenge and drawback to ICIT, and presents right management strategies for very complex complications. Moreover, for the first time in literature, a non-linear mathematical model is introduced to measure the ICIT success rate and to decide about the optimum ICIT duration. Furthermore, a strategy is presented to overcome or to delay the progression after initial good response in a subset of patients.

show abstract

“…Immunotherapy based on innate immunity has attracted a lot of attention recently. − Because the innate immune system is the first nonspecific line of defense against infection and malignant cell transformation, it could significantly increase the beneficiary population of immunotherapy. , A very important function of innate immunity is to use the phagocytic capacity of innate immune cells, such as macrophages and dendritic cells (DCs), to clear damaged or senescent cells, or even more, tumor cells . Therefore, strategies targeting anti-phagocytosis checkpoints could activate the phagocytic capacity of innate immune cells to realize anti-tumor immunotherapy. , The innate immune system directs downstream inflammatory responses by rapidly detecting microbial proteins or membrane molecules of tumor cells .…”

Section: Introductionmentioning

confidence: 99%

Enhanced Immunotherapy Based on Combining the Pro-phagocytosis and Anti-phagocytosis Checkpoint Blockade for Tumor Eradication

Song

Yang

et al. 2022

J. Med. Chem.

View full text Add to dashboard Cite

Compared to the activation of acquired immunity by the immune checkpoint blockade, the activation of innate immunity via anti-phagocytosis checkpoint blockade could significantly increase the beneficiary population of immunotherapy. However, the activation of innate immunity and the occurrence of phagocytosis are only accomplished when the interaction between pro-phagocytosis signals and anti-phagocytosis signals is realized. Herein, a versatile nanoplatform (DHMR) based on mesoporous silicon nanoparticles (MSNPs) has been constructed. Two drugs, doxorubicin, a chemotherapeutic drug which could initiate tumor cells to release pro-phagocytosis signals, and RRx-001, an immunoadjuvant that could effectively implement the anti-phagocytosis checkpoint blockade, were loaded in MSNPs. Further decoration of hyaluronic acid encapsulation endows DHMR with the function of tumor targeting and long circulation. Ultimately, the DHMR system could efficiently and accurately target tumor tissue, release the drugs in the tumor microenvironment, achieve the activation of innate immunity, and finally dramatically inhibit the growth and metastasis of tumor cells.

show abstract

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Cited by 29 publications

References 26 publications

Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Strategy Against Tumor Plasticity

Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Strategy Against Tumor Plasticity

Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy Against Tumor Plasticity

Enhanced Immunotherapy Based on Combining the Pro-phagocytosis and Anti-phagocytosis Checkpoint Blockade for Tumor Eradication

Contact Info

Product

Resources

About